Healthcare Funding Roundup: Where Investors Are Placing Their Bets

Start your week strong with our roundup of the latest funding news in the healthcare industry. Stay informed about the innovative companies and groundbreaking technologies reshaping the future of healthcare. We've got you covered from cutting-edge medical devices to game-changing digital health solutions. Dive in and stay ahead of the curve!

News

Health Catalyst (Nasdaq: HCAT), a Salt Lake City, UT-based provider of data and analytics technology and services to healthcare organizations, acquired Carevive Systems, a Boston, MA-based oncology-focused health technology company.

Done Global, a telehealth startup supported by venture capitalist David Sacks, has come under legal scrutiny as its founder and lead physician were arrested on charges of unlawfully dispensing Adderall and other stimulant medications.

Funding

Santa Ana Bio, Inc. , a precision immunology company based in Alameda, CA, has raised $168 million across Series A and B funding rounds. The Series A was led by founding investor Versant Ventures, with participation from TPG's Life Science Innovations fund and GV. The subsequent $125 million Series B round was led by GV, with all existing investors contributing alongside new investors Access Biotechnology, Andreessen Horowitz (a16z) Bio + Health, and RTW. Santa Ana Bio plans to use the funds to expand its operations and research and development efforts.

Kardium Inc. , a Vancouver-based company developing the Globe? Mapping and Ablation System for treating atrial fibrillation, has raised $104 million in new financing. The funding round was led by the existing investor Fidelity Management & Research Company, with follow-on participation from funds and accounts advised by T. Rowe Price Associates, Inc. and T. Rowe Price Investment Management, Inc., as well as a new investor, Durable Capital Partners LP. Kardium plans to utilize the raised capital to complete its PULSAR clinical study, obtain regulatory approvals for the Globe System, expand its manufacturing team and capacity, and build a clinical support and commercial team in preparation for the commercial launch of the Globe System, which is designed to revolutionize the treatment of atrial fibrillation.

Alzheon, Inc. | Preserving Future Memories , a Framingham, Massachusetts-based company founded in 2013 that focuses on developing treatments for Alzheimer's disease, has secured $100 million in Series E funding. Alerce Medical Technology Partners led the round. This significant investment underscores the continued interest in advancing solutions for neurodegenerative diseases.

Amber Therapeutics , a three-year-old London-based startup, raised $100 million in a Series A funding round. The investment was led by NEA, with additional participation from prominent investors, including F-Prime Capital, Lightstone Ventures, Intuitive Ventures, Oxford Science Enterprises, and 8VC. This significant influx of capital from prestigious venture capital firms and existing investors will enable Amber Therapeutics to advance its innovative work further and accelerate its growth trajectory within the biotechnology industry.

InduPro , a biotechnology company based in Seattle, WA, and Cambridge, MA, has raised $85 million in Series A funding to develop novel therapeutics for cancer and autoimmune diseases. The round was led by The Column Group and Vida Ventures, with participation from MRL Ventures Fund, Emerson Collective, and Euclidean Capital. The funds will support the advancement of InduPro's first clinical product candidate targeting cancer tissue based on co-targeted pair proximity, aiming for an IND filing in Q4 2025 and subsequent Phase 1 clinical trial. Additionally, the capital will fuel the development of a pipeline of bispecific antibodies and antibody-drug conjugates (ADCs) that leverage protein proximity to identify novel tumor-selective target pairings.

Enveda , a Boulder-based startup focused on discovering natural medicinal compounds for disease treatment, has secured a $55 million Series B2 funding round. This five-year-old company's innovative approach to drug development has attracted investments from prominent entities such as Microsoft, The Nature Conservancy, Premji Invest, and Lingotto Investment Fund, alongside continued support from previous investors, including Kinnevik, True Ventures, FPV, Level Ventures, and Jazz Venture Partners. Enveda Biosciences has raised a remarkable $230 million with this latest financing round, solidifying its position as a pioneering force in natural product-based therapeutics.

AVAVA , a Waltham, Massachusetts-based medical aesthetics platform company, has secured $35 million in financing. The funding round comprises $25 million from new and existing investors, including strategic partner Jeisys Medical, Inc., and $10 million in growth capital from Catalio Capital Management. Avava plans to use the funds to accelerate the commercialization of its flagship product, MIRIA, a new class of aesthetic dermatology lasers. MIRIA utilizes proprietary Focal Point Technology? to deliver energy, representing an innovation in dermatology lasers.

Adcytherix , a Marseille, France-based biopharmaceutical company specializing in developing novel antibody-drug conjugates (ADCs), has secured €30 million in a seed funding round. Pontifax led the investment, which was participated in by Pureos Bioventures, RA Capital Management, Dawn Biopharma (a platform controlled by KKR), and the company's management team. Adcytherix will use the funds raised to fuel its operations' expansion and accelerate its development efforts, further advancing its innovative ADC therapeutics pipeline.

Moleculent , a Stockholm-based company providing a functional biology platform, has raised $26 million in a Series A funding round. The investment was co-led by ARCH Venture Partners and Eir Ventures, with participation from existing investors. Moleculent plans to utilize the raised capital to expand its operations and strengthen its research and development efforts, further enhancing its innovative functional biology platform and solutions.

Anterior , an AI-powered healthcare administration platform based in New York City, has raised $20 million in a Series A funding round. The investment was led by New Enterprise Associates, with participation from Sequoia Capital, Blue Lion Global, and Neo. Mohamad Makhzoumi, co-CEO of NEA, will join Anterior's board of directors. The company plans to utilize the newly raised funds to accelerate hiring efforts and implement growth strategies to expand its platform and operations.

Better Health , a San Francisco-based medical supply and support provider, has raised $14 million in funding from investors, including Healthworx, UHealth – University of Miami Health System, and Mosaic General Partnership. This financing round, which follows the company's previous $10 million Series A, also saw participation from new investor Samsung Next and existing investors such as Caffeinated Capital, General Catalyst, Bill Ackman's family office Table Management, and at.inc/ . Better Health plans to use the funds to develop a more comprehensive solution for payers and providers while expanding into new categories to serve members with chronic conditions.

Canary Speech , an AI-powered voice biomarker health tech company based in Provo, UT, has secured $13 million in a Series A funding round. The investment was led by Cortes Capital (Love's Private Equity), with participation from Sorenson Communications, SMK, and Hackensack Meridian Health. Canary Speech will utilize the raised capital to expand its team and support its growth, driven by advancements in artificial intelligence and the increasing demand from the healthcare industry for more advanced tools. The company's technology leverages AI to analyze voice biomarkers, providing innovative solutions for the healthcare sector.

Grayce , a San Francisco-based social care platform, has raised $10.4 million in Series A funding led by Maveron, with participation from various investors, including BBG Ventures, Correlation Ventures, GingerBread Capital, Alumni Ventures, Visible Ventures, Gaingels, and What If Ventures. Founded by Julia Cohen Sebastien and Kassidee Kipp, Grayce aims to support family caregivers by reducing stress and helping them navigate caregiving complexities. The platform assigns each member a dedicated social worker who manages comprehensive care needs, from planning and prioritizing to resource identification, care coordination, and advocacy. Grayce plans to use the funds to scale its platform, enhance its employer solution and member experience, and enter the payer market. The company's services can assist families with various caregiving scenarios, such as managing eldercare needs for an aging parent, including housing, in-home support, care financing, treatment options, and social support.

Auxilius , a New York City-based clinical trial financial management (CTFM) software provider, has secured $10 million in a funding round led by SignalFire. The company plans to use the capital to expand its operations and intensify its development efforts, further enhancing its CTFM software solutions designed to streamline financial operations for clinical trials.

IgniteData , a decade-old UK-based company, has secured an $8 million seed funding round led by SpringTide, with participation from Oncology Ventures. IgniteData's innovative platform streamlines patient data from electronic health records to electronic data capture systems, enabling efficient and automated data transfer for clinical trials. This seed investment will further empower IgniteData to enhance its cutting-edge technology, accelerating the clinical trial process and facilitating more seamless and accurate data management. With its proven track record and industry-leading solution, IgniteData is poised to revolutionize how patient data is handled in clinical research, ultimately contributing to developing life-saving treatments and therapies.

Alida Biosciences , a San Diego-based company pioneering innovative epigenomic research tools, has raised $7.5 million in a Series A funding round. Genoa Ventures led the investment, joined by FusionX Ventures and Vertical Venture Partners. Alida Biosciences will use the capital to enhance its product development efforts further and facilitate the commercialization of its EpiPlex kit, bringing this cutting-edge epigenomic research solution to markets worldwide.

Rivia, a Zurich-based startup specializing in AI-driven analytics and clinical trial data infrastructure for biotechnology companies, has raised €3 million in a seed funding round. The investment was led by Speedinvest, with participation from Amino Collective and Nina Capital. Rivia plans to utilize the raised funds to expand its engineering and client services teams, advance product development, and solidify its position as a unified data platform for clinical trials in the biopharma industry. The company's AI-powered solutions aim to streamline and enhance clinical trial data management for biotechnology firms.

Real World Health , a London-based healthcare data analytics company, has raised ￡1.7 million in Series A funding. The round was led by Maven Capital Partners, with participation from Dowgate Capital. Real World Health plans to use the funds to expand its operations and business reach, likely to enhance its position in the healthcare data analytics market.

Apex Infusion, a provider of ambulatory infusion therapy services based in Signal Hill, CA, has received an undisclosed investment from FFL Partners. While the specific amount was not revealed, the company plans to utilize the newly acquired funds to expand its operations and development efforts to grow its infusion therapy services. This investment from FFL Partners, a private equity firm, will enable Apex Infusion to scale its business and explore new ambulatory infusion therapy market opportunities.

Scilife , an Antwerp, Belgium-based company providing a quality management system for the life sciences sector, has received an undisclosed growth investment from Five Elms Capital. While the specific amount was not revealed, Scilife plans to use the funding to consolidate its market presence and drive further adoption of its innovative electronic quality management system (eQMS) solution. This capital injection from Five Elms Capital, a private equity firm, will enable Scilife to strengthen its position in the life sciences industry and accelerate the deployment of its eQMS platform designed to streamline quality management processes.

Apricot Technologies, an Oklahoma City-based startup that harnesses generative AI to streamline healthcare documentation, has secured undisclosed funding. Cortado Ventures led the investment round. Apricot Technologies plans to utilize the raised capital to expand its operations and intensify its development efforts, further enhancing its innovative solution that aims to reduce the documentation burden in the healthcare industry through the application of generative AI technology.

Augnito , a Dubai-based company offering medical voice AI solutions, has received an undisclosed investment from Dharmendra Ghai. Augnito will utilize the funds raised through this deal to accelerate the development and deployment of its healthcare technologies. These solutions aim to enhance patient experiences and improve operational efficiency across the global healthcare continuum, leveraging the power of voice AI to drive innovation in the medical field.

GenomesDAO, a London-based biotech company focused on secure, private, and auditable monetization of genomic data, has raised an undisclosed amount of funding in a new round. Pantera Capital and Modular Capital led the investment. GenomesDAO plans to utilize the raised capital to accelerate its direct-to-consumer (DTC) efforts while developing its virtual labs concurrently. This funding will support the company's mission of enabling individuals to monetize their genomic data securely and transparently.

Omniscent, a Sydney-based company using AI to decode the human brain, has raised an undisclosed amount in a Series C funding round, bringing the total raised to $60 million. An undisclosed investor participated in the latest round. Led by CEO Stephen Scheeler, Omniscent (o8t?) utilizes AI in connectomics to decode and map the brain's networks responsible for functions such as motor, language, and emotion using MRI scans. The company's flagship platform, Quicktome, uses AI to map these brain networks automatically. Omniscent recently expanded its product offerings to include the first FDA-cleared neurological planning and visualization tool using resting-state fMRI. It opened new applications for Quicktome in areas like stroke, disorders of consciousness, and oncology. The raised funds will be used to expand Omniscent's presence in the US market, where over 100 hospitals and clinics already use Quicktome. Additionally, the funds will support the company's product development efforts to target expanded indications and further enhance its AI-powered brain mapping capabilities.

Koda Health , a Houston-based company specializing in digital advance care planning, has secured an undisclosed amount in Seed+ funding. The round was led by Ecliptic Capital, with participation from Memorial Hermann Health System, AARP, and the Texas Medical Center (TMC) Venture Fund. Koda Health plans to use the funds to expand its operations and business reach, furthering its mission in the digital healthcare sector.

Leo Cancer Care , a medical device company based in Horley, UK, has secured an undisclosed amount in Series C funding from investors, including McLaren Health Care Corporation, Cone Health, Wisconsin Alumni Research Foundation, Macmillan Cancer Support, and Aviko Radiopharmaceuticals. The company plans to use the funds to expand into Asian markets, specifically Singapore, Japan, and South Korea, where it has already begun building teams and establishing a commercial presence.

Funds

Foresite Capital , a San Francisco-based multi-stage healthcare and life sciences investment firm led by founder and CEO Jim Tananbaum, has closed its sixth fund at $900 million , bringing its total assets under management to over $3.5 billion. Fund VI, backed by a diverse group of limited partners, including endowments, foundations, medical institutions, pension funds, and family offices worldwide, focuses on investing in growth-oriented companies within precision therapeutics, life science infrastructure, and healthcare delivery. With investments in companies such as Alumis, Latigo Biotherapeutics, Inc., CG Oncology, RayThera, and Xaira Therapeutics, Foresite Capital aims to address unmet medical needs by funding promising healthcare and life sciences businesses throughout their life cycles.

InTandem Capital Partners , a New York City-based middle-market private equity firm specializing exclusively in healthcare services, has successfully closed its InTandem Capital Partners Fund III, LP, raising $715 million in total capital commitments. Fund III attracted a diverse group of existing and new investors, including leading endowments, foundations, family offices, healthcare and pension systems, and financial institutions from across the globe. Consistent with its previous funds, Fund III will continue its established strategy of making control investments in North American payor, provider, and pharmaceutical services businesses, utilizing an operationally intensive, hands-on value creation model. InTandem partners closely with founders, entrepreneurs, and management teams to drive transformational growth through its collaborative approach.

J.P. Morgan Private Capital has successfully closed its inaugural fund, amassing $500 million to invest in pioneering biotech startups. This substantial fund will adopt a flexible and agnostic approach without constraints regarding the target companies' stage, location, or focus areas. However, the fund plans to make 20 to 25 early-stage investments, strategically targeting startups in cardiometabolic disease, immunology, oncology, and genetic medicine. With this dedicated fund, J.P. Morgan Private Capital aims to catalyze innovation and drive transformative advancements in these critical healthcare domains, fostering the development of groundbreaking therapies and solutions that could potentially improve countless lives.

SCI Ventures Inc. , a venture philanthropy firm based in London, UK focused on funding and commercializing innovative treatments for spinal cord injury, has launched its first fund. The co-founders include prominent organizations such as the Christopher & Dana Reeve Foundation, Wings for Life, the International Spinal Research Trust, the Promobilia Foundation, and Shepherd Center. With initial commitments of $27 million and an anticipated $40 million by the end of the year, the fund aims to advance breakthroughs for individuals living with paralysis by supporting promising therapies and emerging technologies oriented toward finding a cure for spinal cord injuries.